diclofenac + orphenadrine + paracetamol

DORP is a fixed-dose combination pharmaceutical product developed by Verisfield for the symptomatic relief of acute painful musculoskeletal conditions, specifically low back pain. The formulation combines three active ingredients with complementary pharmacological profiles: diclofenac sodium, orphenadrine citrate, and paracetamol. Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) that provides analgesic and anti-inflammatory effects by inhibiting cyclooxygenase (COX) enzymes, thereby reducing prostaglandin synthesis. Orphenadrine citrate acts as a centrally acting skeletal muscle relaxant with anticholinergic and NMDA receptor antagonist properties, helping to alleviate muscle spasms associated with acute pain. Paracetamol serves as an additional analgesic and antipyretic agent, likely acting through central mechanisms to enhance the overall pain-relieving effect. This triple combination is designed to address both the inflammatory and spasmodic components of musculoskeletal disorders.

Brand names

DORP

Other names

diclofenac sodium + orphenadrine citrate + paracetamol